Nearly all of the changes proposed by the U.S. advantage corporate entities by expanding monopolies on knowledge goods, such as drug patents, and impose restrictive copyright policies worldwide. If it came into force, TPP would even allow pharmaceutical companies to sue the U.S. whenever changes to regulatory standards or judicial decisions affected their profits.
Professor Brook K. Baker of Northeastern U. School of Law [said] that the latest version of the TPP will do nothing less than lengthen, broaden, and strengthen patent monopolies on vital medications.
This place just isn't big enough for all of us. We've got to find a way off this planet.